Clinical performance of automated chemiluminescent methods for anticardiolipin and anti-β2-glycoprotein I antibodies detection in a large cohort of Chinese patients with antiphospholipid syndrome
- 1 April 2020
- journal article
- research article
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 42 (2), 206-213
- https://doi.org/10.1111/ijlh.13156
Abstract
Introduction To assess the clinical performance and correlations of automated chemiluminescence assay (CIA) and enzyme-linked immunosorbent assay (ELISA) for detecting antiphospholipid (aPL) antibodies in the diagnosis of antiphospholipid syndrome (APS). Methods The study recruited 505 subjects, including 192 with APS, 193 with connective tissue diseases other than APS, and 120 healthy donors. We measured anticardiolipin (aCL) and anti-beta 2-glycoprotein I (anti-beta 2GPI) antibodies IgG, IgM, and IgA in all the samples using both CIA and ELISA. Results Total agreement between the two methods ranged from 83.50% for anti-beta 2GPI IgG antibodies to 92.76% for anti-beta 2GPI IgM antibodies in all the groups. Anti-beta 2GPI and aCL IgG assays showed the highest Spearman's rho coefficients (anti-beta 2GPI IgG = 0.742, aCL IgG = 0.715). Anti-beta 2GPI IgG CIA showed the highest sensitivity for diagnosis of APS at 80.21%, which was significantly higher than the sensitivity of anti-beta 2GPI IgG ELISA (52.08%). For diagnosis of APS, anti-beta 2GPI IgG CIA had the best discrimination power with the area under the curves (AUC) of 0.922, followed by aCL IgG CIA (AUC of 0.905). While the CIA AUC was slightly higher in all cases, the difference was not statistically significant. Conclusion CIA measurements had a good agreement and correlation with comparative ELISA assays. The CIA anti-beta 2GPI IgG however was significantly more sensitive for APS diagnosis. The two assay methodologies showed comparable predictive powers and support the value of the CIA method for improved diagnosis and management of patients with APS.Funding Information
- National Natural Science Foundation of China (81671589, 81801602, 81871272)
This publication has 31 references indexed in Scilit:
- Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndromeThrombosis Research, 2011
- Guidelines for antiphospholipid antibody detectionNature Reviews Rheumatology, 2011
- Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called ‘seronegative APS’)Annals Of The Rheumatic Diseases, 2011
- Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndromeJournal of Thrombosis and Haemostasis, 2010
- European attempts for the standardisation of the antiphospholipid antibodiesLupus, 2009
- A protocol for determination of anticardiolipin antibodies by ELISANature Protocols, 2008
- Antiphospholipid antibody ELISAs: Survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-β2-Glycoprotein I activityThrombosis Research, 2007
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- The anticardiolipin assay is required for sensitive screening for antiphospholipid antibodiesJournal of Thrombosis and Haemostasis, 2004
- Comparison of different kits in the detection of autoantibodies to cardiolipin and 2-glycoprotein 1: comment on the article by Audrain et al.Rheumatology, 2004